ReviewAutoimmunity reviews2020
COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?
Review in Autoimmunity reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
146 citing papers in PubMed, 4 syntheses or guidelines pooled it, 279 citations in OpenAlex.
- Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis.Journal of critical care · 2022Pooled it
- Systemic inflammation in COVID-19 patients may induce various types of venous and arterial thrombosis: A systematic review.Scandinavian journal of immunology · 2021Pooled it
- Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review.JAMA network open · 2021Pooled it
- Pooled it
- Effectiveness and safety of cyclosporine A in moderate to severe COVID-19: a randomized, open-label trial.Scientific reports · 2026Trial
- Hyperinflammatory nutritional index as an exploratory combined inflammatory and nutritional marker: associations with cytokines and β2-microglobulin in COVID-19.BMC infectious diseases · 2026Observational
- Targeting macrophage ferritin heavy chain mitigates ferroptosis and lung injury in experimental acute respiratory distress syndrome.Nature communications · 2026Article
- Inflammatory biomarkers and adverse outcome in COVID-19: Prelude for future viral pandemics.Journal of family medicine and primary care · 2025Article
- Dynamic ferritin levels and survival outcomes in secondary hemophagocytic syndrome: a comprehensive analysis.Frontiers in medicine · 2025Article
- The Role of Vitamins, Magnesium, and Trace Elements in COVID-19 Treatment and Post-COVID-19 Rehabilitation: An Updated Overview.Current medicinal chemistry · 2025Review
- Development of a laboratory-based nomogram for predicting clinical outcomes in patients with severe COVID-19 undergoing glucocorticoid therapy.Frontiers in medicine · 2025Article
- Serum ferritin as a predictive marker of pulmonary fibrosis in post-COVID-19.Qatar medical journal · 2025Article
- Taurolithocholic acid protects against viral haemorrhagic fever via inhibition of ferroptosis.Nature microbiology · 2024Article
- Persistent ENT Manifestations in Individuals who Recovered from COVID-19: A Systematic Review.International archives of otorhinolaryngology · 2024Review
- Still's Disease Onset in Older Adults: Clinical Features, Diagnosis, and Management.Drugs & aging · 2024Review
- Fever and dyspnea after anti-Covid-19 vaccination: a challenging diagnosis.Internal and emergency medicine · 2024Article
- Can iron chelators ameliorate viral infections?Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024Review
- Point-of-care lung ultrasound predicts hyperferritinemia and hospitalization, but not elevated troponin in SARS-CoV-2 viral pneumonitis in children.Scientific reports · 2024Article
- Mechanisms of Ferritinophagy and Ferroptosis in Diseases.Molecular neurobiology · 2024Review
- Two versus three doses of COVID-19 vaccine and post-vaccination COVID-19 infection in hemodialysis patients.Infection prevention in practice · 2024Article
86 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The severe form of COVID-19 share several clinical and laboratory features with four entities gathered under the term "hyperferritinemic syndromes" and including macrophage activation syndrome (MAS), adult-onset Still's disease (AOSD), catastrophic anti-phospholipid syndrome (CAPS) and septic shock. COVID-19 systemic inflammatory reaction and "hyperferritinemic syndromes" are all characterized by high serum ferritin and a life-threatening hyper-inflammation sustained by a cytokines storm which eventually leads to multi-organ failure. In this review, we analyze the possible epidemiological and molecular mechanisms responsible for hyper-inflammation in patients with severe COVID-19 and we underline the similarities between this condition and "hyperferritinemic syndromes" which would allow considering severe COVID-19 as a fifth member of this spectrum of inflammatory conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.